Compare Merck & Co., Inc. (MRK) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Merck & Co., Inc. trades at $141.96 (market cap $351.28B), while Direxion Daily TSLA Bull 2X Shares trades at $10.33 (market cap $3.97B). The key difference: Merck & Co., Inc. is far larger — about 88.5× Direxion Daily TSLA Bull 2X Shares's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| MRK | TSLL | |
|---|---|---|
Market Cap | $351.28B | $3.97B |
Volume | 7,969,665 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $23.03 |
52-Week Low | $82.49 | $6.74 |
Typical Hold Time | 98 Days | 15 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.15, down 1.55% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights its sensitivity to Tesla's performance, with a rally noted ahead of the Cybercab event. The ETF's structure amplifies daily returns, making it highly volatile and dependent on Tesla's stock movements.
The outlook for TSLL is tied directly to Tesla's stock volatility and news flow. Investment opportunities exist for traders seeking leveraged exposure to Tesla's upside, but risks include significant volatility decay and the potential for amplified losses. Investors should be cautious of the ETF's daily reset mechanism, which can lead to underperformance over time compared to holding Tesla stock directly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
